EUVIMEDEUVIMED entdecken
KorrekturOpen Access

Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”

Obesity · 2026-06 · 34 (6) · 1354-1354

DOI: 10.1002/oby.70194 ↗

Kurz gefasst

Korrektur in der Zeitschrift Obesity, online erschienen am 22.03.2026. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”. Obesity, 34(6), 1354-1354. https://doi.org/10.1002/oby.70194

Vancouver

Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”. Obesity. 2026;34(6):1354-1354. doi:10.1002/oby.70194

BibTeX
@article{euvimed2026,
  title = {Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”},
  journal = {Obesity},
  year = {2026},
  volume = {34},
  number = {6},
  pages = {1354--1354},
  doi = {10.1002/oby.70194}
}
Kostenlos starten →